

<b>FORM PTO-1449</b> <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>INT'L FILING NO.</b>		<b>PCT/GB2005/000939</b>	
				<b>INT'L FILING DATE</b>		<b>March 10, 2005</b>	
				<b>APPLICANT</b>		<b>Mark James Bamford</b>	
				<b>GROUP</b>		<b>1624</b>	
				<b>EXAMINER</b>		<b>Coleman</b>	
				<b>ATTORNEY DOCKET NO.</b>		<b>PB60780USw</b>	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Examiner Initials</b>		<b>Patent Number</b>	<b>Issue Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>
/B.C./	1.	4,210,749	7/1/1980	Shetty	542	469	
/B.C./	2.	5,364,791	11/15/1994	Vegeto et al.	435	320.1	
/B.C./	3.	5,874,534	2/23/1999	Vegeto et al.	530	350	
/B.C./	4.	5,935,934	8/10/1999	Vegeto et al.	514	44	
<b>FOREIGN PATENT DOCUMENTS</b>							
		<b>Document Number</b>	<b>Publication Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation Yes   No</b>
** /B.C./	5.	WO96/05194	2/22/1996	PCT			abstract only
/B.C./	6.	WO00/21951	4/20/2000	PCT			
** /B.C./	7.	WO00/23437	4/27/2000	PCT			abstract only
/B.C./	8.	WO01/03680	1/18/2001	PCT			
** /B.C./	9.	WO01/87834	11/22/2001	PCT			abstract only
** /B.C./	10.	WO02/02530	1/10/2002	PCT			abstract only
** /B.C./	11.	WO02/14513	2/21/2002	PCT			abstract only
** /B.C./	12.	WO02/15934	2/28/2002	PCT			abstract only
** /B.C./	13.	WO02/46186	6/13/2002	PCT			abstract only
/B.C./	14.	WO02/040471	5/23/2002	PCT			
/B.C./	15.	WO02/059115	8/1/2002	PCT			
/B.C./	16.	WO03/068752	8/21/2003	PCT			
/B.C./	17.	WO04/018432	3/4/2004	PCT			
/B.C./	18.	WO04/056369	7/8/2004	PCT			
/B.C./	19.	1268243	3/22/1972	GB			
** /B.C./	20.	2207430	8/23/1973	DE			no
/B.C./	21.	0612741	8/31/1994	EP			
** /B.C./	22.	2171879	9/28/1973	FR			no
** /B.C./	23.	2001226269	8/21/2001	JP			no
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>							
/B.C./	24.	FUKUIJ et al., Molecular Cloning of the Human Histamine H <sub>1</sub> Receptor Gene, Biochem and Biophy Res. Comm., <b>201(2)</b> :894-901 (1994).					
/B.C./	25.	AUSTIN et al., Novel 2,3,4,5-Tetrahydro-1H-3-benzazepines with High Affinity and Selectivity for the Dopamine D <sub>3</sub> Receptor, Bioorg. & Med. Chem Ltrs. <b>10</b> :2553-2555 (2000).					
/B.C./	26.	SMIT et al., Regulation of the human histamine H <sub>1</sub> receptor stably expressed in Chinese hamster ovary cells, Br. J. Pharmacol. <b>117(6)</b> :1071-1080 (1996).					
/B.C./	27.	GIOVANNINI et al., "Effects of histamine H <sub>3</sub> receptor agonist and antagonists on cognitive performance and scopolamine-induced amnesia," Behavioral Brain Res. <b>104</b> :147-155 (1999).					
/B.C./	28.	LEURS et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists," TiPS <b>19</b> :177-183 (May 1998).					
/B.C./	29.	LOVENBERG et al., "Cloning and Functional Expression of the Human Histamine H <sub>3</sub> Receptor," Molecular Pharmacology <b>55</b> :1101-1107 (1999).					
/B.C./	30.	ONODERA and WATANABE, "Histamine H <sub>3</sub> Antagonists as Potential Therapeutics in the CNS," ed Leurs and Timmerman, pp255-267, Elsevier Science B.V. (1998).					
/B.C./	31.	SARLO and RENZI, 2-Methylisoxazolin-5-Ones-II, Tetrahedron <b>22</b> :2995-2999 (1966).					
/B.C./	32.	SCHLICKER et al., Modulation of Neurotransmitter Release via histamine H <sub>3</sub> heteroreceptors, Fund. Clin. Pharmacol. <b>8</b> :128-137 (1994).					
EXAMINER /Brenda Coleman/					DATE CONSIDERED 09/02/2008		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

\*\* Structures only